Clinical trial

A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)

NCT03333018

Study summary

ClinicalTrials.gov

A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Aclidinium bromide Normalized identity: aclidinium bromide View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Aclidinium bromide/formoterol Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Other COPD medication Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2015-07-06

PhaseN/A

Conditions

Pulmonary Disease, Chronic Obstructiveunresolved

Interventions

Aclidinium bromideDRUG · verified · RxNorm: aclidinium bromide

Aclidinium bromide/formoterolDRUG

Other COPD medicationDRUG

Sponsors & collaborators

AstraZenecalead sponsor

RTI Health Solutionscollaborator

Mapped research locations

LondonUnited Kingdom1 OdenseDenmark1 BremenGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03333018 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.